EGFR and neoplasm: The observation that LATS1/2 KO by CRISPR/Cas9 confers resistance to EGFR inhibitors in vitro and in vivo [78] indicate that YAP/TAZ reactivation by an unknown mechanism after EGFR inhibitor treatment plays an important role in HNSCC initial resistance or tumor recurrence.